Order Article Reprints

LeBlanc R, Thiant S, Terra R, Ahmad I, Claveau J-S, Bambace N, Bernard L, Cohen S, Delisle J-S, Lachance S, et al. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant. Current Oncology. 2024; 31(11):7258-7274. https://doi.org/10.3390/curroncol31110535

LeBlanc, Richard, Stéphanie Thiant, Rafik Terra, Imran Ahmad, Jean-Sébastien Claveau, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Silvy Lachance, and et al. 2024. "A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant" Current Oncology 31, no. 11: 7258-7274. https://doi.org/10.3390/curroncol31110535

LeBlanc, R., Thiant, S., Terra, R., Ahmad, I., Claveau, J.-S., Bambace, N., Bernard, L., Cohen, S., Delisle, J.-S., Lachance, S., Kiss, T., Roy, D.-C., Sauvageau, G., & Roy, J. (2024). A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant. Current Oncology, 31(11), 7258-7274. https://doi.org/10.3390/curroncol31110535